BioControl Medical Makes Progress Toward FDA Review for CardioFit Heart Stim Device

Tue, 03/26/2013 - 1:27pm
Mass Device

The FDA approves the 3rd and largest phase of BioControl Medical's investigational device exemption trial of the CardioFit vagal nerve stimulation device.

BioControl Medical logo

Israel and Minnesota-based BioControl Medical won FDA approval to proceed with the 3rd and largest phase of its INOVATE-HF trail, evaluating its CardioFit vagal nerve stimulation system in treatment of heart failure.

The global, multi-center trial aims to provide clinical data in support of BioControl's premarket approval application for FDA clearance of the CardioFit system, according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.